Brain and Mind Centre, The University of Sydney, Sydney, Australia.
Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, Australia.
Cannabis Cannabinoid Res. 2022 Jun;7(3):294-303. doi: 10.1089/can.2021.0027. Epub 2021 Jun 28.
Medicinal cannabis has proliferated around the world and there is increasing interest in the therapeutic potential of individual plant-derived cannabinoids (phytocannabinoids). Preclinical evidence suggests the phytocannabinoid cannabigerol (CBG) could be useful in treating brain disorders, including stress and anxiety-related disorders. In this study, we aimed to explore whether CBG disrupts various contextually conditioned fear memory processes and trauma-induced anxiety-related behavior in a mouse model of post-traumatic stress disorder (PTSD). All mice underwent contextual fear conditioning. CBG was administered between 1 and 60 mg/kg intraperitoneally (i.p.). We first assessed the effects of repeated CBG exposure on long-term fear memories. We also examined whether acute CBG affected various fear memory processes, namely expression, acquisition, consolidation, and reconsolidation of conditioned fear. Finally, the effect of acute CBG administration on stress-induced anxiety in the light/dark test was assessed. Repeated CBG exposure did not affect long-term conditioned fear that was observed 24 days after the conditioning session. Moreover, acute CBG administration did not influence the acquisition, consolidation, reconsolidation, or expression of contextually conditioned fear. Acute CBG treatment also did not affect stress-induced anxiety-related behaviors in the light/dark test. CBG was ineffective in disrupting long-term fear memories, various conditioned fear memory processes, or stress-induced anxiety-related behavior in mice. These preclinical data suggest CBG may have limited scope in the treatment of PTSD and stress-related anxiety.
医用大麻在全球范围内迅速普及，人们对植物源性大麻素（植物大麻素）的治疗潜力越来越感兴趣。临床前证据表明，植物大麻素大麻萜酚（CBG）可能对治疗包括应激和焦虑相关障碍在内的脑部疾病有用。在这项研究中，我们旨在探索 CBG 是否会破坏创伤后应激障碍（PTSD）小鼠模型中各种条件性恐惧记忆过程和创伤引起的焦虑相关行为。所有小鼠均接受情境性恐惧条件反射。通过腹膜内（i.p.）给予 CBG，剂量为 1 至 60mg/kg。我们首先评估了重复 CBG 暴露对长期恐惧记忆的影响。我们还检查了急性 CBG 是否会影响各种恐惧记忆过程，即条件性恐惧的表达、获得、巩固和再巩固。最后，评估了急性 CBG 给药对明亮/黑暗测试中应激诱导的焦虑的影响。重复 CBG 暴露不会影响 24 天后观察到的条件性恐惧的长期记忆。此外，急性 CBG 给药不会影响条件性恐惧的获得、巩固、再巩固或表达。急性 CBG 治疗也不会影响明亮/黑暗测试中的应激诱导的焦虑相关行为。CBG 不能破坏长期恐惧记忆、各种条件性恐惧记忆过程或应激诱导的焦虑相关行为。这些临床前数据表明，CBG 在治疗 PTSD 和应激相关焦虑方面的应用范围可能有限。
